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ChemoresistanceEpigenetic silencing mechanisms play an important role in chemoresistance of human cancer. Here
we report the upregulated expression of metastasis-associated protein 1 (MTA1), a component of the
nucleosome remodeling deacetylation (NuRD) complex, in chemoresistant prostate cancer (PCa).
MTA1 knockdown in PC-3 cells inhibited cell proliferation and enhanced docetaxel (DTX)-induced
cell death. Conversely, overexpression of MTA1 promotes DTX chemoresistance in PC-3 cells.
MTA1 acted as a potent corepressor of the nuclear receptor NR4A1 transcription by interacting with
histone deacetylase 2 (HDAC2). These ﬁndings suggest that MTA1 may serve as a novel DTX-resis-
tance promoter in PC-3 cells.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction plays a central role in the regulation of divergent cellular pathwaysProstate cancer (PCa) causes substantial morbidity and mortal-
ity worldwide and has become one of the leading male cancers in
some Asian countries [1]. As prostate cancer progresses it becomes
refractory to hormone manipulation. At this stage, chemotherapy
remains the main treatment option in the setting of castration-
resistant prostate cancer (CRPC), providing modest survival and
palliative beneﬁts [2]. Among different chemotherapies, docetaxel
(DTX) chemotherapy offers both symptomatic and survival bene-
ﬁts in men with metastatic hormone-refractory PCa. However,
resistance to such chemotherapy will eventually develop in
approximately half of the patients, and the disease then becomes
difﬁcult to control [3–5]. The precise mechanisms of this phenom-
enon have not been clearly elucidated up to date. Preclinical and
clinical evidence suggests that multiple mechanisms are certain
to coexist to confer DTX chemoresistant phenotypes [6,7].
Metastasis-associated protein 1 (MTA1), a component of the
Mi-2/nucleosome remodeling deacetylation (NuRD) complex,by modifying the acetylation status of crucial target genes [8,9]. In
PCa, MTA1 expression is higher in hormone-refractory metastatic
PCa compared to clinically localized disease and benign prostatic
tissues [10]. MTA1 pro-angiogenic and pro-invasive functions cre-
ate a permissive environment for PCa tumor growth and likely sup-
port metastasis by regulating the expression of E-cadherin [11].
Recent advances demonstrated that phosphatase and tensin homo-
log (PTEN), a master tumor suppressor gene during PCa pathogen-
esis, is also the transcriptional regulation target of MTA1. MTA1
transcriptionally represses PTEN expression by recruiting class II
histone deacetylase along with the transcription factor Yin-Yang
1 (YY1) onto the PTEN promoter [12]. In addition, many recent re-
ports in this ﬁeld have demonstrated the functional importance of
MTA1 in PCa progression and metastasis at both the in vitro and
in vivo levels [13–15]. Based on these ﬁndings, enhanced expres-
sion of endogenous MTA1 has been implicated in promoting PCa
tumorigenesis, and MTA1 can also be utilized both as a prognostic
marker and a therapy target in PCa [12].
NR4A orphan receptors, including NR4A1 (Nur77, TR3, NGFI-B),
NR4A2 (Nurr1), and NR4A3 (Nor1), are members of the nuclear
receptor (NR) superfamily of transcription factors, and regulate
several key biological pathways in cancerous tissues [16]. Knock-
down of NR4A1 resulted in inhibition of cell growth, induction of
apoptosis, and decreased angiogenesis, suggesting that NR4A1 is
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observations was observed in LNCaP cells, where antisense-medi-
ated knockdown of NR4A1 appeared to increase cell growth [17].
Consistent with the last line of evidence, microarray studies have
identiﬁed that downregulation of NR4A1 was in favor of cancerous
metastasis [18]. These data collectively are indicative of a unique
role of NR4A1 in PCa.
Accumulatedevidencesuggests that theandrogen-refractoryPCa
proliferates faster than the androgen-sensitive cancer. Also, the
androgen-refractory PCa has been generally considered as chemore-
sistant [19]. On the other hand, emerging data point to a potential
involvement of deacetylases in the chemoresistant phenotypes of
PCa [20]. Considering the close relationship betweenMTA1 function
and recruitment of histone deacetylation complexes during tran-
scriptional regulation, we hypothesized thatMTA1may be involved
in the pathogenesis of PCa chemoresitance. A functional andmecha-
nistic study comprisingmultiple analyseswas therefore designed to
elucidate the potential links between this chromatin modiﬁer and
the aggressive nature of chemoresistant PCa. In addition, since
upregulation of MTA1 and downregulation of NR4A1 are both
strongly associatedwith cancerousmetastasis, and NR4A1 has been
shown tobe transcriptionally regulatedbyhistonedeacetylase com-
plexes [21], we then evaluated the potential functional association
between MTA1 and NR4A1. Our systematic analysis will pave the
way for a better understanding of the role of MTA1 in PCa.
2. Materials and methods
2.1. Patients
Samples have been obtained after patients gave written in-
formed consent. In detail, benign prostatic tissues from patients
who underwent radical cystoprostatectomy due to bladder cancer
(n = 5) and biopses from CRPC patients (n = 30) were included. The
chemoresistant PCa patients were deﬁned as CRPC patients with
tumors clearly progressing on after 4 cycles of three-weekly ﬁrst-
line DTX-based chemotherapy (patients were treated with DTX
chemotherapy 75 mg/m2 intravenously on day 1 repeated every
three weeks along with prednisolone 10 mg daily). Androgen sup-
pression with LHRH analogues was continued throughout the
duration of chemotherapy. General characteristics of PCa patients
are summarized in Supplementary Table 1 (note: The Gleason
score system, which was developed by Dr. Donald Gleason in the
1960s, is used to help evaluate the prognosis of men with prostate
cancer. A Gleason score is given to prostate cancer based upon its
microscopic appearance. Cancers with a higher Gleason score are
more aggressive and have a worse prognosis. This system consists
of ﬁve grades, and is measured on a scale of 1–5. Pathologists usu-
ally assign a grade to the most common tumor pattern, and a sec-
ond grade to the next most common tumor pattern. The two grades
are added together to get a Gleason Score. The Gleason Grade
ranges from 1 to 5, with 5 having the worst prognosis. The Gleason
Score ranges from 2 to 10, with 10 having the worst prognosis
[22,23]). After collection, tissues were either immediately ﬁxed in
10% neutral buffered formalin for histochemical examination or
stored at 80 C for biochemical analysis. The use of the human
tissue in this study was approved by the Human Research Commit-
tee of the Fourth Military Medical University (Permit number:
10002). The protocol employed strictly conformed to the standards
set by The 2008 Revised Declaration of Helsinki.
2.2. Cell culture and treatment
LNCaP and PC-3 cells were purchased from ATCC. Normal hu-
man prostate epithelial cells (PEC) were purchased from Clonetics.
Cells were maintained in RPMI-1640 medium supplemented with10% Fetal Bovine Serum (FBS) (Invitrogen). PC-3 resistant sub-lines
(PC-3R) were generated as described elsewhere [24]. Speciﬁc
knockdown of MTA1 was achieved by transfecting PC-3 with corre-
sponding siRNA against MTA1 (sc-35981) or with a control siRNA
(sc-37007) (Santa Cruz Biotechnology, CA). Brieﬂy, 2  105 PC-3
cells were cultured in six-well culture plates and transfected with
siRNA against MTA1 (which consist of pools of three to ﬁve target-
speciﬁc 19–25 nt siRNAs) or the same amount of non-target
control siRNA following the manufacturer’s protocol. 48 h after
transfection, cells were collected and subjected to other experi-
ments. pCMV6-AC-GFP-tagged NR4A1 plasmid was purchased from
OriGene. PC-3 cells stably overexpressing exogenous MTA1 or
NR4A1 were established according to a previous report [25].
2.3. Cell viability measurement
Ten thousand cells/well were cultured in a 96-well plate. 24 h
later, cells were treated with different concentrations of DTX (Sig-
ma–Aldrich) for different durations. Cells were then subjected to
MTT assay for viability measurement.
2.4. Assessment of apoptosis
Apoptotic events were assessed by Annexin V–FITC/PI staining
followed by FACS as described [25]. An apoptosis ELISA kit (Roche
Diagnostics, Mannheim, Germany) was also used to quantitatively
measure cytoplasmic histone-associated DNA fragments (mononu-
cleosomes and oligonucleosomes). Brieﬂy, cells were incubated in
a microplate well with 5 nM DTX for 24 h and were then pelleted
by centrifugation. Cells were resuspended in lysis buffer. After ly-
sis, an aliquot of the supernatant was transferred to a streptavi-
din-coated well of a microplate. The nucleosomes in the
supernatant were incubated with two monoclonal antibodies,
anti-histone (biotin-labeled) and anti-DNA (peroxidase-conju-
gated), at room temperature for 2 h. The antibody-nucleosome
complexes are bound to the microplate by the streptavidin. The ﬁ-
nal spectrophotometric assay was developed using peroxidase sub-
strate and the absorbance was measured in triplicate with a
microplate reader at 405 nM (Bio-Rad680).
2.5. Promoter reporter assay
Luciferase assays were performed using a human MTA1 pro-
moter reporter construct system (SwitchGear Genomics, Menlo
Park, CA) according to the manufacturer’s instructions (nucleotides
777 to +242; Genbank accession number: U35113). The human
NR4A1 promoter region (Nucleotides 869 to +123; Genbank
accession number: U17590.1) was generated by PCR ampliﬁcation
using human genomic DNA [26] and cloned into the pGL3 lucifer-
ase reporter vector (Promega, Madison, WI) with the Infusion 2.0
Dry-Down PCR cloning kit (Clontech). The primers used are listed
in Supplementary Table 2. Cells were transiently transfected with
1 lg of plasmid DNA using Lipofectamine 2000 (Invitrogen). For
the assessment of NR4A1 promoter activity, cells were also
co-transfected with pcDNA3.1-His-MTA1 or pcDNA3.1-His. The
pRL-TK Renilla reporter plasmid (Promega) was co-transfected to
normalize the transfection efﬁciency. Luciferase activity measure-
ments were performed using the dual-luciferase reporter assay
system (Promega) according to the manufacturer’s protocol. The
ﬁreﬂy luciferase activity was normalized according to the Renilla
luciferase activity and expressed as relative luciferase units (RLU)
to reﬂect the promoter activity [27].
2.6. Colony formation assay
Approximately 400 cells (transformed with the PC-3-His-vector
or PC-3-His-MTA1)/60-mm plastic dish (Falcon; Becton Dickinson,
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sphere of 5% CO2 and 95% air. At the end of 48 h of incubation,
DTX (5 nM) was added to the cultures. After 3 days treatment,
the DTX-containing media was replaced with fresh media and all
cultures were incubated for an additional 9 days until colonies
were large enough to be clearly discerned. Colonies were stained
for 5 min with a solution containing 0.5% crystal violet and 25%
methanol, followed by three rinses with tap water to remove ex-
cess dye. The colonies, deﬁned as groups of >50 cells, were ﬁnally
scored using Colony Counter software (Syngene, Frederick, MD).
The average number of colonies was plotted (Mean ± S.D., n = 3).
2.7. In vivo nude mouse tumor xenograft model
1  106 cultured PC-3-His-vector or PC-3-His-MTA1 trans-
formed cells in 200 ll PBS were injected subcutaneously in
8-week-old nude mice (n = 6 mice per group). Equivalent volumes
of PBS were injected as an experimental control. At the 4th week
after cell inoculation, mice were subjected to intraperitoneal injec-
tions of DTX in 10% DMSO, at a dose of 25 mg/kg B.W. every 24 h
for 3 weeks. Control mice received 10% DMSO alone. Tumor vol-
ume changes were recorded weekly by two perpendicular diame-
ter measurements as described [28]. Animal work was approved
by the Ethics Committee for Animal Experiments of the Fourth Mil-
itary Medical University (Permit number: 10001).
2.8. RT-PCR and quantitative RT-PCR (qRT-PCR)
RT-PCR and qRT-PCR were carried out as described [29]. In brief,
total RNA was extracted using RNeasy Mini Kit (QIAGEN Inc.,
Valencia, CA, USA) and ﬁrst-strand cDNA was synthesized with
Superscript II (Rnase H- Reverse Transcriptase; Invitrogen). PCR
was set up according to Promega’s reverse transcription system
protocol. Details of primers used are listed in Supplemental Table 2.
Ampliﬁcation of 18S RNA served as internal control. PCR products
were quantiﬁed by SYBR green intercalation using the MiniOpti-
con™ system (Bio-Rad Laboratories, CA, USA). The relative abun-
dance of each target transcript was quantiﬁed using the
comparative 44Ct method.
2.9. Western blotting
Western blotting was carried out as described previously [29].
Brieﬂy, protein samples were prepared in ice-cold RIPA buffer
(Tris–HCl 50 mM, NaCl 150 mM, Triton X-100 1% vol/vol, sodium
deoxycholate 1% wt/vol, and SDS 0.1% wt/vol pH 7.5) supple-
mented with complete proteinase-inhibitor cocktail tablets (Roche
Diagnostic, Mannheim, Germany). 20 lg of protein sample were
separated by SDS/PAGE and transferred to a nitrocellulose
membrane (Millipore, Bedford, MA, USA). Membranes were then
incubated with different primary antibodies as indicated in Sup-
plemental Table 3, with b-actin serving as internal control. Final
signals were detected using an ECL kit (Amersham Biosciences,
Buckinghamshire, UK) according to the manufacturer’s
instructions.
2.10. Immunohistochemistry
The streptavidin–biotin complex (SABC) immunohistochemical
method was conducted as previously described [29]. Primary anti-
bodies used are listed in Supplemental Table 3. Immunostaining of
MTA1 in human PCa samples was evaluated using a Q500 com-
puter-assisted image analysis system (Leica, USA). In total, 50 unit
areas in ﬁve sections in each age group were measured using a 40
objective. The optical densities of the MTA1 immunoreactive
deposits were determined. At the end of the analysis for eachgroup, the mean optical density of each unit area was automati-
cally calculated by the computer. Quantiﬁcation of Ki67 staining
was carried out as described elsewhere [30]. Brieﬂy, immunoposi-
tivity and immunonegativity were determined using a linear dis-
criminant analysis based on hue, saturation, and intensity of 500
immunostained cells and 200 cells of a negative control slide,
respectively. The positivity for Ki67 was deﬁned as the total num-
ber of pixels from immunopositive areas divided by the total num-
ber of pixels from all nuclear areas detected in a given specimen.
2.11. Chromatin immunoprecipitation
The ChIP assay was performed according to previous work [29].
The sequence of primers and the antibodies used are listed in Sup-
plementary Tables 2 and 3, respectively.
2.12. Statistical analysis
Data from in vitro experiments were compared using Student’s t
test. The signiﬁcance of differences between the growth curves in
the xenograft model for tumor volume changes was assessed by
analysis of variance (ANOVA). Statistical analyses were performed
using SPSS 15.0 software with P < 0.05 being considered as statisti-
cally signiﬁcant.
3. Results
3.1. Upregulation of MTA1 expression in chemotherapy-resistant PCa
In the ﬁrst attempt to study the potential involvement of MTA1
in the chemoresistance of PCa, we examined the expression level of
MTA1 mRNA in human PCa specimens. RT-PCR analysis revealed
that the MTA1 transcripts were detectable in a panel of human
prostate benign and tumor tissues (Fig. 1A). Subsequent qRT-PCR
analysis demonstrated thatMTA1mRNA was signiﬁcantly elevated
in chemoresistant PCa samples (n = 15) compared to their chemo-
sensitive counterparts (n = 15) and benign tissues (n = 5) (Fig. 1B).
Immunohistochemical analysis demonstrated a signiﬁcant in-
crease of MTA1 expression in the nuclei of chemoresistant PCa cells
(Fig. 1C). Further quantitative analysis conﬁrmed the upregulation
of MTA1 expression in chemoresistant PCa samples (Supplemen-
tary Table. 4). We then generated DTX-resistant sublines (PC-3R).
PC-3R cells demonstrated partial but increasing resistance to DTX
treatment over the different doses, when compared to the PC-3
cells (Supplementary Fig. 1). We then assessed MTA1 expression
levels in different human prostatic cell lines. PEC and LNCaP cells
showed the lowest levels of MTA1, whereas the higher expression
levels were found in PC-3 and PC-3R cells, with the highest level
observed in PC-3R cells (Fig. 1D and E). Moreover, to investigate
the transcriptional activity of theMTA1 gene in different cell types,
human MTA1 promoter reporter constructs were transfected into
different PCa cells. Luciferase activity was measured 48 h after
transfection. PC-3R cells showed the highest promoter activity
(12.68 ± 2.12 RLU) when compared to other cells (Fig. 1F). These
data are indicative of an association of elevated MTA1 expression
with chemoresistance in PCa.
3.2. Endogenous MTA1 protects PC-3 cells from DTX-induced death
We next explored the role of MTA1 in the DTX-induced cytotox-
icity in PC-3 cells, because these cells represent a more resistant
phenotype. We transiently knocked down MTA1 in PC-3 cells using
siRNA treatment (Fig. 2A and B). The viability of these cells in re-
sponse to DTX treatment was then analyzed by MTT assay. Abla-
tion of MTA1 in PC-3 cells resulted in a 50% drop in cell viability
at 22 h post-treatment, whereas the control group only lost about
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Fig. 1. Upregulation of MTA1 in chemoresistant prostate cancer (PCa). (A) Expression ofMTA1 in human prostate tissues. Total RNA was isolated from benign, chemosensitive
and chemoresistant human prostate tissues and subjected to reverse transcription-PCR (RT-PCR) as described in Section 2. (B) Relative expression levels of MTA1 in human
prostate tissues were quantiﬁed using quantitative RT-PCR (qRT-PCR). (C) Immunohistochemical staining of MTA1 in human prostate tissues. NC, negative control
experiments using preabsorbed anti-MTA1 antibody. (D) Relative expression levels ofMTA1 in normal human prostate epithelial cells (PEC), LNCaP, PC-3 and PC-3R cells were
quantiﬁed using qRT-PCR. (E) The level of MTA1 protein in PEC, LNCaP, PC-3 and PC-3R cells was detected by Western blotting. b-Actin served as a loading control. (F) The
MTA1 promoter activity was determined using a commercially available human MTA1 promoter reporter construct system according to the manufacturer’s instruction.
L. Yu et al. / FEBS Letters 587 (2013) 2542–2551 254534% viability 24 h after the same DTX treatment (Fig. 2C). In addi-
tion, ELISA methods revealed that MTA1 knockdown led to signif-
icant increase of apoptosis after cells had been incubated with DTX
(5 nM) for 24 h (Fig. 2D). This elevated apoptotic rate was further
conﬁrmed by the upregulated expression of proteolytic PARP frag-
ment in the MTA1-siRNA treated cells, in which the pro-survivalAkt signaling was inhibited (Fig. 2E). We also used another siRNAs
from Sigma (Cat. SASI_Hs01_00239682 and SASI_Hs01_00239683)
to exclude potential off-targets effects in the knockdown experi-
ment. About 70% of endogenous MTA1 was efﬁciently knocked
down by this siRNA (Supplementary Fig. 3A and B). ELISA methods
showed that MTA1 knockdown led to a signiﬁcant increase of
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2546 L. Yu et al. / FEBS Letters 587 (2013) 2542–2551apoptotic rate after cells had been incubated with DTX (5nM) for
24 h (Supplementary Fig. 3C). Collectively, these data indicate that
endogenous MTA1 may protect PC-3 cells from chemotherapeutic
insult.
3.3. Overexpression of MTA1 enhances DTX resistance in PC-3 cells
To further assess whether enhanced MTA1 expression is
causative of or a result of chemotherapy-resistance in PCa, we
overexpressed His-tagged MTA1 in PC-3 cells (Fig. 3A) and then
incubated these cells with 5 nM DTX for 24 h. DTX-induced apop-
tosis was signiﬁcantly attenuated in the cells overexpressing
His-tagged MTA1 when compared to that in control cells
(Fig. 3B). Conversely, higher colony formation efﬁciency wasdetected after DTX treatment in PC-3 cells overexpressing His-
tagged MTA1 (Fig. 3C). In the tumor xenograft study, we implanted
subcutaneously cells overexpressing His-tagged MTA1 or His-
vector at the back of nude mice. Starting at the 4th week after cell
inoculation, mice were treated with DTX (25 mg/kg B.W. every
day) administered intraperitoneally for another 4 weeks. We ana-
lyzed tumor size on a weekly basis for 8 weeks and the tumor
weight on week 8 after tumor cell injections. Data showed a signif-
icant difference in tumor size from week 6 afterwards (⁄P < 0.05)
(Fig. 3D). Consistently, signiﬁcant changes in tumor weight were
observed at week 8 (Fig. 3E). The higher proliferation rate and
lower apoptotic status of prostate tumors derived from cells over-
expressing His-tagged MTA1 were conﬁrmed using immunohisto-
chemical staining of Ki67 and immunoblotting analysis of cleaved
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ulation of MTA1 expression could inﬂuence the proliferation and
clonogenicty in PC-3 cells upon cytotoxic stress.
3.4. Augmentation of MTA1 expression by DTX treatment represses the
expression of NR4A1 in PC-3 cells
In an effort to search for the potential mechanism underlying
the role of MTA1 in chemoresistance in PC-3 cells, we found a sig-niﬁcant reduction of NR4A1 expression in PC-3R cells with ele-
vated levels of MTA1 (data not shown), raising the possibility
that MTA1 might be an upstream regulator of the NR4A1 signaling.
To verify this, we treated cells overexpressing His-tagged MTA1 or
His-vector with 5nM DTX. The transcriptional level of NR4A1 in
cells expressing His-vector was notably increased during the ﬁrst
2 h of DTX incubation. In contrast, we did not ﬁnd a signiﬁcant in-
crease of NR4A1 expression in cells overexpressing His-tagged
MTA1 during the study period (Fig. 4A). This expression proﬁle
2548 L. Yu et al. / FEBS Letters 587 (2013) 2542–2551was conﬁrmed at the translational level by immunoblotting
(Fig. 4B). In line with this observation, the relative expression level
of NR4A1 mRNA in cells depleted of endogenous MTA1 remained
continuously high in response to DTX treatment (Supplementary
Fig. 2). MTA1 efﬁciently repressed the NR4A1 transcriptional activ-
ities in DTX treated PC-3 cells as measured by promoter reporter
assay (Fig. 4C). To conﬁrm that the NR4A1 gene chromatin is a di-
rect target of MTA1, we performed ChIP assays, using primers
encompassing different fragments of the NR4A1 promoter region.
MTA1 was recruited to the 318 to 31 bp region of the NR4A1
promoter after 4 h of DTX treatment (Fig. 4D). Because MTA1 en-
gages HDAC complexes to repress transcription, we performed a
double ChIP in DTX treated PC-3 cells to further demonstrate the
physical interaction of the MTA1/nucleosome remodeling and his-
tone deacetylase complex with the NR4A1 chromatin. We found
simultaneous co-association of MTA1 and HDAC2 with the NR4A1A
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Fig. 4. MTA1 regulates NR4A1 expression. PC-3 cells overexpressing exogenous MTA1
expression levels of NR4A1were then evaluated using qRT-PCR (A) andWestern blotting (
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expressed as means ± S.D. ⁄P < 0.05. (D) ChIP analysis showing recruitment of MTA1 onto
complex on NR4A1 promoter in PC-3 cells. (F) A working model depicts that MTA1 is achromatin, and its gradual de-recruitment by increasing doses of
TSA. MTA1 recruitment to the NR4A1 promoter at 4 h of DTX treat-
ment was more robust that at the 1 h of DTX treatment, well con-
sistent with the NR4A1 expression level in DTX treated PC-3 cells
expressing His-vector (Fig. 4B and E). Collectively, our results indi-
cated that MTA1 represses NR4A1 expression in an HDAC-depen-
dent manner in DTX treated PC-3 cells (Fig. 4F).
3.5. Ectopic overexpression of NR4A1 enhances chemosensitivity to
DTX in PC-3R cells
Previous study showed that inhibition of NR4A1 expression in-
creases viability of PCa cells upon cytotoxic stress [17]. In our
study, we overexpressed GFP-tagged NR4A1 and its control vector
in PC-3R cells (Fig. 5A), and then incubated the cells with DTX
(20 nM) for 24 h. Annexin V/PI double staining and FACS analysisB
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a speciﬁc region of the NR4A1 promoter. (E) Double ChIP analysis of MTA1/HDAC2
negative regulator of NR4A1 transcription.
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centage of early apoptotic cells induced by DTX (Fig. 5B). Therefore,
it is possible that NR4A1 may be terminally responsible for the
pathogenesis of chemoresistance caused by MTA1 upregulation
in PC-3 cells.
4. Discussion
Upregulation of MTA1 has been associated with increased risk
of breast, liver, and more recently with highly progressive prostate
cancer [9]. However, whereas deregulation of MTA1 may inﬂuence
prostate cancer progression, few studies have examined MTA1 pro-
tein expression in prostate cancer tumor tissue [13–15]. Hofer and
colleagues had addressed this important point, and they found that
metastatic PCa demonstrated signiﬁcantly higher mean MTA1 pro-
tein expression intensity compared with clinically localized PCa or
benign prostate tissue [10]. Additionally, our results, showing that
MTA1 upregulation is also involved in the differential response to
DNA damage agents and is positively associated with chemoresis-
tant PCa and higher Gleason score, can also explain why the evolu-
tion of the disease could be favored by the elevation of MTA1
expression. Mechanistically, MTA1 functions as an essential tran-
scriptional coregulator. This may explain why most of the positive
signals of upregulated MTA1 expression were immunolocalized inA
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Fig. 5. Overexpression of exogenous NR4A1 increases the chemosensitivity of PC-
3R cells. Overexpression of exogenous GFP-tagged NR4A1 in PC-3R cells was
conﬁrmed by immunoblotting for GFP. Expression of MTA1 was not affected (A).
Cells were incubated with DTX (20 nM) for 24 h and the apoptotic status was then
determined using Annexin V/PI double staining followed by FACS analysis (B).the nuclear (Fig. 1C) [8]. In line with the human tissue data, MTA1
expression level was higher in PC-3 cells than that in LNCaP and
PEC cells. This is understandable, since androgen-sensitive LNCaP
cells are susceptible to apoptosis but androgen-insensitive PC-3
cells are relatively resistant to chemotherapy [31]. MTA1 expres-
sion and transcriptional activities were even more robust in exper-
imentally produced chemoresistant PC-3R cells, further validating
the potential involvement of MTA1 expression in the pathogenesis
of PCa chemoresistance.
Emerging evidence points to a frequent participation of deacet-
ylases in tumor chemoresistance. For example, loss of class III beta-
tubulin induced by histone deacetylation is associated with
chemosensitivity to paclitaxel in malignant melanoma cells [32].
The interaction between HA/CD44-stimulated p300 (acetyltrans-
ferase) and resveratrol-activated deacetylase plays pivotal roles
in regulating the balance between multidrug resistance and sensi-
tivity in breast tumor cells [33]. More recently, upregulation of
SIRT1, a transcriptional coregulator belonging to the family of type
III histone deacetylases, has been shown to play a key role in pro-
moting chemoresistance in androgen-refractory PC-3 and DU145
cells [17]. Although the mechanisms whereby MTA1 expression
is up-regulated in chemoresistant PC-3 cells remain to be deﬁned,
several regulators have been so far reported to determine the level
of MTA1 expression. For example, E3 ubiquitin ligase COP1 regu-
lates the stability and functions of MTA1 [34]. Emerging data sug-
gest that E3 ubiquitin ligases are frequently overexpressed in
human cancers, which correlates well with increased chemoresis-
tance and poor clinical prognosis [35]. Similarly, it was previously
reported that miR-661 inhibits MTA1 expression and negatively
regulates its function [36]. There is increasing evidence that
drug-induced dysregulation of microRNA (miRNA) function may
modulate the sensitivity of cancer cells to chemotherapeutic
agents, and may be involved in the acquisition of cancer cell resis-
tance to chemotherapy [37]. Thus, deregulation of E3 ubiquitin li-
gase or miRNA may at least in part explain the elevated expression
of MTA1 in response to DTX treatment.
MTA1 acts as a component of the NuRD complex and plays an
essential role in chromatin remodeling and transcriptional regula-
tion of genes [9]. It is therefore a logical hypothesis that this chro-
matin modiﬁer may directly participate in PCa chemoresistance.
Our results showed that siRNA mediated MTA1 knockdown in
PC-3 cells inhibited the ability to proliferate or to resist apoptosis,
and thereafter resulted in signiﬁcant cell death upon DTX
treatment. In contrast, the overexpression of exogenous MTA1 sub-
stantially promoted cell proliferation and protected cells from
DTX-induced apoptosis. In a subcutaneous xenograft implantation
mouse model to assess in vivo drug sensitivity, overexpression of
MTA1 enhanced the chemoresistance of PCa cells and led to a sig-
niﬁcant increase of the tumor burden. These data support our
emerging view that MTA1 probably serves as a key transcriptional
regulator during the pathogenesis of chemoresistance in PC-3 cells.
Of note, the effect of MTA1 overexpression on PC-3 cell prolifera-
tion in the absence of DTX treatment appeared to be associated
with the cell density initially seeded. When we used 400 cells
(PC-3-His-vector or PC-3-His-MTA1)/60-mm plastic for the colony
formation assay, we did not ﬁnd a signiﬁcant effect of overexpres-
sion of MTA1 on cell proliferation rate (Fig. 3C). However, we did
ﬁnd a signiﬁcant increase in the colony formation rate in the ab-
sence of DTX treatment if we seeded cells at 1200 cells/60-mm
plastic (Supplementary Fig. 4). Two possibilities may account for
this observation. First, higher density cell culture may result in a
hypoxic environment. Hypoxia induces MTA1 expression, and
MTA1 could enhance the stability and activity of hypoxia-inducible
factor-1a (HIF-a), thus promoting tumor growth under hypoxic
condition [38]. Moreover, the effect of MTA1 overexpression on
the state of cell proliferation may be closely regulated by cellular
2550 L. Yu et al. / FEBS Letters 587 (2013) 2542–2551interactions. In favor of the latter hypothesis, it has been reported
that the hyaluronan-mediated motility receptor (HMMR) and E-
cadherin, two key components of extracellular matrix (ECM) mol-
ecules regulating the motility, invasion, and metastatic potential of
cancer cells, are both tightly regulated by MTA1 [11,39]. The rele-
vance of the potential crosstalk between MTA1 overexpression and
hypoxia/cellular contact in the regulation of cell proliferation in
the absence of genotoxic insult is yet to be further deﬁned.
Many apoptosis-inducing drugs induce nuclear export of NR4A1
and activate apoptosis in cancer cell lines [13]. It has been shown
that antisense-mediated knockdown of NR4A1 increased LNCaP
cells growth in response to etoposide treatment, indicating a pro-
apoptotic effect of this NR in etoposide-induced PC-3 cell death
[14]. However, the transcriptional or posttranscriptional mecha-
nisms responsible for controlling NR4A1 expression in response
to DNA damage are poorly understood. Our ﬁndings extend these
understanding by identifying MTA1 as a potent corepressor of
NR4A1 transcription [We conﬁrmed the inhibitory effect of endog-
enous MTA1 on NR4A1 transcription in DTX-treated PC-3 cells by
using another siRNA system from Sigma (Supplementary
Fig. 3D)]. Repression of NR4A1 transcription by MTA1-HDAC2
may represent a novel mechanism contributing to the pathogene-
sis of PCa chemoresistance. To be noted, we believe that HDAC2
indirectly binds to the NR4A1 promoter region via ﬁrst binding to
MTA1. There are two lines of evidence supporting this assumption:
(1) In single step ChIP assay, the positive signals of HDAC2 were al-
ways weaker than those for MTA1; (2) In the response to DTX
treatment we could not obtain positive ChIP signals for HDAC2 in
cells depleted of endogenous MTA1 (our unpublished data). Thus,
HDAC2 may exert its transcriptional regulation effect through
interaction with MTA1 in a piggy-back manner (Fig. 4F). Previ-
ously, Uemura, et al., identiﬁed a novel cis-acting element, NCAE-
NR4A1 (200 to 181 nucleotides), in the 50-promoter region of
the NR4A1 gene that is required for the expression of this gene.
Similarly, a DNA fragment very similar to this NCAE-NR4A1 cis-act-
ing element in the promoter area (322 to 151 nucleotides) of
NR4A1, is proved to play a role in apoptosis of mouse T cell hybrid-
omas [14]. Very interestingly, the promoter region of NR4A1 bound
by MTA1 (318 to 31 nucleotides) also included this
NCAE-NR4A1 cis-acting element. The available data broaden our
understanding of the role of NCAE-NR4A1 in PCa apoptosis, and
also provide a mechanistic explanation for the repression of
NR4A1 expression by MTA1 corepressor associated with the HDAC
complexes. In addition, overexpression of exogenous NR4A1 also
reduced the cell killing effect of DTX in PC-3R cells (Fig. 5). This re-
sult may support the hypothesis that MTA1-NR4A1 interaction
contributes to chemotherapeutic sensitization as an alternative
for cancer therapy.
Therapeutic agents commonly used in PCa treatments can dam-
age DNA through various mechanisms. There is a group of agents,
including etoposide, irinotecan, topotecan and DTX, which inhibit
topoisomerases I and II and introduce temporary breaks in the
DNA strands. In this context, prostate cancer is a heterogeneous
disease with a variable natural history that is not accurately pre-
dicted by currently used prognostic tools [33]. Emerging literature
establishes MTA1 to be a valid DNA-damage responsive protein
with a signiﬁcant role in maintaining the optimum DNA-repair
activity in mammalian cells exposed to genotoxic stress [40]. To-
gether with our observations that MTA1 is upregulated in chemo-
resistant PCa, and that MTA1 knockdown in PC-3 cells inhibited
cell proliferation and enhanced DTX-induced cell death, we suggest
that MTA1 affects the chemotherapy response in PCa, thus estab-
lishing a new subset of patients that may require alternative ther-
apies. There has been little progress in the systemic management
of prostate cancer beyond androgen deprivation therapy, and a no-
vel therapeutic approach is urgently needed. To this end, MTA1elevation might confer a more aggressive clinical course for men
with DTX treatment, and personalized interventions may be war-
ranted. Moreover, since NR4A1 is a direct down-stream target of
MTA1 and upregulation of MTA1/downregulation of NR4A1 is clo-
sely associated with chemoresistance in PCa, testing patients for
MTA1/NR4A1 expression ratios may provide more accurate prog-
nostic information and could inﬂuence the recommended course
of treatment.
In summary, we showed here for the ﬁrst time that MTA1 level
is signiﬁcantly elevated in chemoresistant PCa samples, and that
MTA1 promotes DTX resistance in PC-3 cells via its transcriptional
regulation property. A major pathway in this response is the direct
control of NR4A1 transcription, which in turn governs the ability of
MTA1 to reduce genotoxic stress-induced apoptosis in PC-3 cells.
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